Jan. 25, 2022, 09:57 AM Mind Medicine Inc (NASDAQ: MNMD) is trading higher Tuesday morning after the company announced the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application, allowing its Phase 2b dose-optimization trial of MM-120 for the treatment of generalized anxiety disorder to proceed.
Full Answer
Is mindmed stock going public?
It will be the second psychedelics company to go public in the U.S. after the Compass Pathways (Nasdaq: CMPS) IPO last year. Although MindMed stock is available on foreign exchanges, this is the first time the company is trading on the U.S. markets. Here’s everything you need to know…
What is the latest on the mindmed IND?
The previously announced clinical hold on the IND was lifted following MindMed’s responses for additional information related to the participant monitoring protocol in the upcoming study. Participant enrollment for the study is expected to start in early 2022.
What is the price of Mind Medicine (mmedf) stock?
Since then, MMEDF shares have increased by 257.1% and is now trading at $1.25. View which stocks have been most impacted by COVID-19. Who are Mind Medicine (MindMed)'s key executives?
What is the ticker symbol for Mind Medicine (mindmed)?
Mind Medicine (MindMed) trades on the OTCMKTS under the ticker symbol "MMEDF." How do I buy shares of Mind Medicine (MindMed)? Shares of MMEDF can be purchased through any online brokerage account.
What is going on with MindMed stock?
MindMed shares were trading around $5 in early 2021 after the company was officially registered on the NASDAQ. Since then, the stock has been gradually falling, losing 67% of its value in the past year.
Is MindMed a good stock to invest?
Mind Medicine (MindMed) has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is MindMed a good long term stock?
Mind Medicine (MindMed) Inc (MNMD) stock is down -53.44% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. InvestorsObserver's proprietary ranking system, gives MNMD stock a score of 31 out of a possible 100. That rank is influenced by a long-term technical score of 6.
Why is MindMed stock going down?
MindMed stock fell Thursday after the psychedelic drug developer said a Swiss ethics committee cleared the company to begin a study on the effects of the hallucinogen mescaline. The study, set to start this month, adds to the research MindMed (MNMD) is conducting on other psychedelic drugs.
Is MindMed being shorted?
Is Mind Medicine (MindMed)'s short interest increasing or decreasing? Mind Medicine (MindMed) saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 747,300 shares, a decrease of 0.1% from the previous total of 748,300 shares.
How high will mind medicine stock go?
Stock Price Forecast The 5 analysts offering 12-month price forecasts for Mind Medicine (MindMed) Inc have a median target of 5.14, with a high estimate of 10.00 and a low estimate of 3.00.
Can you buy MindMed on Robinhood?
How do I buy shares of Mind Medicine (MindMed)? Shares of MMEDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Is mind medicine a good company?
MNMD is an emerging player in the psychedelic drug space, but it still has a long way to go. Its EPS is expected to remain negative in its fiscal years 2021 and 2022 because its drugs are still in their early development stage. So, we think it's wise to avoid the stock now.
When did MNMD go public?
On Tuesday, April 27th, 2021, the MindMed stock started trading on the Nasdaq Capital Market. On the Nasdaq, the stock trades under the ticker symbol MNMD.
Is Atai stock a good buy?
Out of 10 analysts, 6 (60%) are recommending ATAI as a Strong Buy, 3 (30%) are recommending ATAI as a Buy, 1 (10%) are recommending ATAI as a Hold, 0 (0%) are recommending ATAI as a Sell, and 0 (0%) are recommending ATAI as a Strong Sell.
How has Mind Medicine (MindMed)'s stock performed in 2022?
Mind Medicine (MindMed)'s stock was trading at $1.38 at the beginning of 2022. Since then, MMEDF shares have decreased by 42.0% and is now trading...
Who are Mind Medicine (MindMed)'s key executives?
Mind Medicine (MindMed)'s management team includes the following people: Mr. Jamon Alexander Rahn , Co-Founder, CEO & Director Dr. Miriam Halperi...
Who are some of Mind Medicine (MindMed)'s key competitors?
Some companies that are related to Mind Medicine (MindMed) include 3SBio (TRSBF) , 45525 (CUR.TO) (CUR) , Abattis Bioceuticals (ATTBF) , Abcam...
What is Mind Medicine (MindMed)'s stock symbol?
Mind Medicine (MindMed) trades on the OTCMKTS under the ticker symbol "MMEDF."
How do I buy shares of Mind Medicine (MindMed)?
Shares of MMEDF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBu...
What is Mind Medicine (MindMed)'s stock price today?
One share of MMEDF stock can currently be purchased for approximately $0.80.
How many employees does Mind Medicine (MindMed) have?
Mind Medicine (MindMed) employs 22 workers across the globe.
What is Mind Medicine (MindMed)'s official website?
The official website for Mind Medicine (MindMed) is www.mindmed.co .
About Mind Medicine (MindMed)
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness.
Headlines
UPDATE: Maxim Group On Mind Medicine: Firm Believes Co. Has 'One Of The Most Diverse Pipelines In Psychedelics' With $160M In Cash.
Mind Medicine (MindMed) (OTCMKTS:MMEDF) Frequently Asked Questions
Mind Medicine (MindMed)'s stock was trading at $0.35 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MMEDF shares have increased by 245.7% and is now trading at $1.21. View which stocks have been most impacted by COVID-19.
What is MindMed on the NASDAQ?
In a long-awaited move, psychedelic therapy developer Mind Medicine (or MindMed) ( NASDAQ:MNMD) was registered on the NASDAQ on Tuesday of last week, causing its stock to explode by more than 50% compared to its level earlier in the month.
What is the Phase 2b of MindMed?
Perhaps the most important catalysts for shareholders are the company's three headliner pipeline projects in phase 2 trials. Two of these projects seek to treat conditions like attention deficit hyperactivity disorder (ADHD) and anxiety using LSD, whereas the third is an investigational treatment for addiction using a compound containing ibogaine, a naturally occurring psychoactive found in certain plants. Phase 2b of the LSD-for-anxiety trial will start sometime in Q4. Before that, MindMed will need to file an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA), so investors can expect an appreciable bump in stock price if regulators assent to the trial.
When did Alex start writing for the Fool?
May 4, 2021 at 6:52AM. Author Bio. Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur.
Can MDMA be optimized?
The data confirms that "the dose of MDMA can be optimized using predictors [such as] body weight, sex, age, genetics, personality trait measures, and mood before drug administration.". If you're a pharmacologist or medical professional, that finding might seem a bit obvious.
Where does MindMed work?
The company's operations and research take place in the U.S., Netherlands, Switzerland and Australia. Like many other psychedelic drug companies, none of MindMed's major projects have generated revenue or profit.
What is the ticker symbol for a compass pathways?
The company would trade on the Nasdaq Global Market under the ticker symbol "ATAI.". Compass Pathways ( CMPS ), which is developing a therapy that uses synthetic psilocybin, began trading in September on the Nasdaq Global Market.
Is MindMed stock on the Nasdaq?
MindMed stock turned lower in its Nasdaq listing debut on Tuesday, making it the latest psychedelic drug developer to use a major U.S. exchange as a pathway to raise money and bring new mental-illness and addiction treatments deeper into mainstream.
What is MindMed therapy?
MindMed is a clinical-stage psychedelic medicine and therapy company. It discovers and develops medicines to help patients with mental illnesses and addictions. This includes anxiety and ADHD. On its website, the company shows the different phases its clinical trials are in.
What is the drug that alters your mood?
MDMA is a synthetic drug. Commonly known as Ecstasy or Molly, it can alter mood and perception of your surroundings. It’s similar to stimulants and hallucinogens. According to the National Institute on Drug Abuse, MDMA can produce increased energy, emotional warmth and distorts senses and time perception.
Where was the first study of MDMA?
The study took place at the University Hospital Basel Liechti Lab in Basel , Switzerland. It’s the first study to provide scientific data for predicting responses to MDMA. And the results could help optimize dosing to reduce adverse reactions.
Is MindMed a global company?
But MindMed is a global leader in the psychedelic industry . And the company recently published data of the first study on MDMA dosing.
Does MindMed have revenue?
Some of the psychedelic substances used by MindMed are LSD, MDMA, Psilocybin and DMT. Currently, MindMed has no revenue. This is often typical of a clinical-stage company as none of their therapies are ready for commercial use.
Does CYP2D6 help with MDMA?
Genetic testing for the metabolizing enzyme CYP2D6 helps with dose adjustments. People with a low level can experience greater effects and can benefit from a reduced dose. People with the personality trait of “openness to a new experience” usually showed more positive effects from MDMA.
Is MindMed stock on the NASDAQ?
MindMed stock trades under the ticker symbol MNMD on the Nasdaq. However, the company remains listed on the Neo Exchange under the symbol MMED. Subordinate shares on the OTCQB will change from ticker symbol MMEDF to MNMD. The MindMed Nasdaq IPO announcement sent stock soring in the days leading up to it. After the announcement April 23 that the ...
When did Alex start writing for the Fool?
Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur.
Is Mind Medicine publicly traded?
Mind Medicine is one of just a few publicly traded companies that are pioneering the use of carefully controlled psychedelic chemicals to treat mental illnesses. Its current projects include a pair of phase 2 clinical trials examining the efficacy of drugs like LSD on conditions like anxiety and adult attention deficit hyperactivity disorder (ADHD). Whereas in the past such research might have been heavily restricted, consistently positive results from preliminary investigations are leading to a growing acceptance of the merit of these therapies.
Is LSD linked to genetics?
On May 26, it published a new study that conclusively linked a patient's genetics with how they metabolize LSD. This research paves the way for the company to pursue future work that could eventually lead to its long-standing goal of being able to offer individualized dosing of the drug.
When will the Nasdaq uplisting be approved?
In other words, there was an over 7-month (214 days, 215 days including Friday 23rd) delay between announcing a Nasdaq-uplisting application on September 21st, 2020 and being granted Nasdaq approval on April 23rd, 2021.
Who is Stephen Hurst?
Stephen Hurst was the former CEO of Savant Addiction and is now a sitting board member of MNMD. In an interview with Stephen Hurst from 2015, when he led Savant Addiction, questions arose regarding 18-MC. Stephen Hurst's answers to these questions have been recycled as arguments during the existence of MNMD.